Cleerly and Bunkerhill Health unite in the name of AI-based cardiac imaging evaluations

Two established leaders in artificial intelligence (AI) have announced a new strategic partnership focused on helping more patients access their advanced algorithms. 

Denver-based Cleerly, known for using AI to evaluate coronary CT angiography (CCTA) images, has joined forces with San Francisco-based Bunkerhill Health, pioneers in AI-powered early detection software, to expand the reach of both companies’ FDA-cleared solutions. 

As a result of this partnership, hospitals already partnering with Cleerly will receive the benefits of Bunkerhill Health’s Careblocks technology, which detects and quantifies coronary artery calcium (CAC) scores using routine chest CT exams. Hospitals already partnering with Bunkerhill Health, meanwhile, will be able to use Cleerly scans to learn more about the heart health of patients with high CAC scores.

“We have been deeply impressed by the innovative work Bunkerhill Health has done with AI developed by leading academic medical centers. Their technology perfectly complements our goal to identify patients at risk for cardiovascular disease earlier and more effectively,” James K. Min, MD, founder and CEO of Cleerly, said in a statement. “Together, we are offering health systems a robust, noninvasive view of cardiovascular risk that empowers them to provide better care and improve long-term outcomes.”

“Too many patients with cardiovascular disease remain undiagnosed until it’s too late,” added Nishith Khandwala, co-founder and CEO of Bunkerhill Health. “Our Careblocks solution is designed to help health systems detect at-risk patients earlier and connect them with the care they need. Cleerly provides another piece of the puzzle by enabling sub-millimeter precision in analyzing coronary plaque burden and type, which are critical drivers of heart attacks. Through this partnership, Cleerly and Bunkerhill Health are helping hospitals improve risk stratification and ultimately deliver superior patient care.”

Click here for a video interview with Min to gain a closer look at Cleerly’s history and the company’s mission going forward.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.